Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
BioCurity is a clinical stage biopharmaceutical company with a mission to material...
BioCurity is a clinical stage biopharmaceutical...
REGENXBIO is a leading biotechnology company focused on the development, commercia...
REGENXBIO is a leading biotechnology company fo...
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused o...
Onconova Therapeutics, Inc. is a Phase 3-stage ...
Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committ...
Proteostasis Therapeutics, Inc. is an innovativ...
Sierra Oncology is a clinical stage drug development company advancing targeted th...
Sierra Oncology is a clinical stage drug develo...
Reata is a clinical-stage biopharmaceutical company that develops novel therapeuti...
Reata is a clinical-stage biopharmaceutical com...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
Join the National Investor Network and get the latest information with your interests in mind.